

INDUCTION OF PIGMENTATION IN MOUSE FIBROBLASTS BY EXPRESSION OF HUMAN TYROSINASE cDNA

BY BRIGITTE BOUCHARD, BRYAN B. FULLER,*
SETALURI VIJAYASARADHI, AND ALAN N. HOUGHTON

*From the Memorial Sloan-Kettering Cancer Center, New York, New York 10021;
and *The University of Oklahoma Health Sciences Center,
Oklahoma City, Oklahoma 73190*

Cells of the melanocyte lineage are distinguished by their capacity to synthesize the pigment melanin. Production of melanin is primarily regulated by the enzyme tyrosinase (monophenol, 3,4-dihydroxyphenylalanine: oxygen oxidoreductase, EC 1.14.18.1), and it is presumed that melanin synthesis can be regulated at a number of levels that control both the amount of melanin synthesized and the type of melanin produced. Melanin synthesis occurs principally in specialized organelles, the melanosomes. Thus, the synthesis of melanin is usually restricted to melanocytic cells that contain melanosomes.

In this report, we describe isolation of a full-length cDNA clone encoding human tyrosinase by using a probe homologous to the Pmel 34 cDNA sequence described by Kwon et al. (1). We have transfected and expressed this new human tyrosinase cDNA clone in mouse fibroblasts, and have induced pigmentation in a cell type that does not normally synthesize melanin. Levels of tyrosinase activity in transfected fibroblasts were equivalent to tyrosinase levels in highly pigmented human melanoma cell lines. These tyrosinase-positive fibroblast cell lines demonstrate that melanin synthesis can take place in cells that do not have melanosomes and, therefore, provide a tool for studying the regulation, transport, and processing of tyrosinase.

Materials and Methods

Cell Culture and Cell Lines. Melanoma cell lines were established as previously described (2). TK⁻ L929 cells (mouse fibroblasts) (3) were used for transfection experiments. Cell lines were maintained in Eagle's MEM supplemented with 2 mM glutamine, 0.1 mM nonessential amino acids (aa)¹, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 10% FCS (complete medium). Cells were passaged with trypsin (1 mg/ml) and EDTA (0.2 mg/ml). All cultures were checked regularly for the presence of mycoplasma and contaminated cultures were discarded.

EM. Cell pellets were fixed in Karnofsky's fixative overnight, rinsed in PBS for 1 h, and then post-fixed for 1 h in 1% osmium tetroxide-PBS solution. Cell pellets were dehydrated in graded ethyl alcohol followed by propylene oxide, and embedded in Maraglas-D.E.R. 732 epoxy resin (Dow Corning Corp., Midland, MI). For orientation, 1- μ m thick sections were

This work was supported by the American Cancer Society, the Louis and Anne Abrons Foundation, the Alcoa Foundation, and the National Institutes of Health. Alan N. Houghton is a recipient of a Cancer Research Institute/Benjamin Jacobson Family Investigator Award.

¹ *Abbreviations used in this paper:* aa amino acid; DOPA, dihydroxyphenylalanine; NET, NaCl/EDTA/Tris.

stained with borate-buffered 1% toluidine blue. Thin sections were stained with uranyl acetate followed by lead citrate and were examined with an electron microscope (410 LS; Phillips Electronic Instruments, Inc., Mahwah, NJ).

cDNA Library and Screening. A cDNA library was constructed from 3 μ g of poly(A)⁺ selected mRNA (4) prepared from the human melanotic melanoma cell line SK-MEL-19 (2). Full-length cDNA was synthesized, rendered blunt ended using Klenow enzyme, and tailed with Eco RI linkers (New England Biolabs, Inc., Beverly, MA) (5). The cDNA was then size fractionated on Ultrogel Aca 34 (Pharmacia Fine Chemicals, Piscataway, NJ) (6). cDNA molecules >800 bp were used to construct a library of 3×10^5 recombinants in the λ phage vector gt10 (7). For screening, a 50-base oligonucleotide probe (50-mer, shown below) based on the 5' terminal coding region of the human tyrosinase Pmel 34 cDNA clone (1) was used: 5' GTTCTTAGAGGAGACACAGGCTCTAGGGAAAATGGCCAGCGGAGGTCTGGA 3'.

The oligonucleotide was synthesized on a DNA synthesizer (310 A; Applied Biosystems, Inc., Foster City, CA). The probe was end labeled with γ -[³²P]ATP and T4 polynucleotide kinase (4). Prehybridization and hybridization were carried out at 48°C for 4 and 18 h, respectively, in $6 \times$ NaCl/EDTA/Tris (NET) ($1 \times$ NET is 0.15 M NaCl, 1 mM EDTA, and 15 mM Tris-HCl, pH 8), 0.1% SDS, and $5 \times$ Denhardt's solution (0.1% BSA, 0.1% Ficoll 400, 0.1% polyvinylpyrrolidone), and 100 μ g/ml of denatured salmon sperm DNA. Duplicate filters were washed in $6 \times$ NET, 0.1% SDS at room temperature, followed by stringent washes at 55°C and 60°C. The filters were then autoradiographed for 4 h at -70°C.

DNA Sequencing. Plaque-purified phage DNA was restricted with Eco RI, and cDNA inserts were subcloned into the plasmid-vector pUC 18 (8). Recombinant plasmids and deletion subclones subsequently obtained by digestion with exonuclease III/Mung Bean nuclease (9) were sequenced by the dideoxynucleotide chain termination method (10).

Northern Blot Analysis. Poly (A)⁺-mRNA (4 μ g) was fractionated on 1% formaldehyde denaturing agarose gels (4), transferred to Gene Screen Plus membranes (New England Nuclear, Boston, MA), and hybridized to a ³²P-labeled cDNA probe. The filters were washed twice at room temperature in $2 \times$ SSC ($1 \times$ SSC is 0.15 M NaCl, 0.015 M sodium citrate, pH 7) and 1% SDS, then stringent washes were carried out at 55°C in $1 \times$ SSC, 1% SDS, and at 65°C in $0.1 \times$ SSC, 1% SDS, for 15 min each.

Transfection Experiments. The cDNA inserts were subcloned into the Eco RI site of the expression vector pcEXV-3, which allows expression of cDNA under the control of SV40 early region promoter and enhancer sequences (11). Expression plasmids containing cDNA inserts in opposite orientations (5'→3' or 3'→5') were constructed. Sense and antisense oriented plasmids were designated pcTYR and pcTYW, respectively. L929 cells were cotransfected by the calcium phosphate precipitation technique (12) with pUC 18, pcTYW or pcTYR, the pSV2 *neo* plasmid, and high molecular weight carrier DNA from L929 cells. Selection of transfectants was started on day 3 after transfection with 1 mg/ml of the antibiotic G418 (Sigma Chemical Co., St. Louis, MO). Complete medium with G418 was replaced every 3 d, and colonies appearing on days 10–14 were isolated using cloning rings and were then expanded. The mouse origin of transfected cell lines was confirmed by positive anti-mouse Ig mixed hemadsorption assays using H100-5R28, an mAb directed against H-2K^k (mouse MHC class I antigens) (13), and lack of reactivity with mAb M3-68 (14) or AJ2 (15), which recognize virtually all human melanoma cells but not L929 cells (data not shown).

Serological Reagents and Assays. CF21 (IgG1) and TA99 (IgG2a) are mAbs, which have been previously described (16), that recognize distinct antigens in human melanosomes. The mAb 2G10 (IgG2a) (17) was a generous gift from Dr. P. G. Natali, (Regina Elena Cancer Instituto, Rome, Italy). This antibody recognizes a 75-kD intracellular glycoprotein of pigmented melanotic cells (17). mAb AJ2 (IgG1) recognizes the β subunit of human integrin molecules (15, 18). Rabbit antityrosinase antiserum was raised by immunization with purified mouse tyrosinase (19). Briefly, tyrosinase was purified by DEAE ion exchange chromatography followed by sequential discontinuous PAGE. The anti-mouse Ig hemadsorption assays and the indirect immunofluorescence studies were performed as described (2, 20).

Immunoprecipitations. Cells were labeled with ³⁵S-methionine (ICN Radiochemicals, Irvine, CA) for 16 h in methionine-free complete medium containing 2% dialyzed FCS, and lysed in 50 mM Tris, 5 mM EDTA, 0.5% NP-40, 1 mM PMSF. The lysates were precleared

twice by incubation with 5 $\mu\text{g}/\text{ml}$ of protein A-Sepharose (Pharmacia Fine Chemicals) for 30 min at 4°C. Immunoprecipitations were performed by incubating the lysates with antibodies, followed by addition of protein A-Sepharose. The immunoprecipitates were extensively washed and analyzed for molecular size by SDS/PAGE (21) under reducing conditions.

Tyrosinase Activity and Melanin Assays. Cells were solubilized in PBS, 1% NP-40, pH 6.8, and centrifuged to obtain clear supernatants. Tyrosine hydroxylase activity was assayed using a modification of the method described by Pomerantz (22). Briefly, the reaction mixture contained 1 $\mu\text{Ci}/\text{ml}$ [^3H]tyrosine (54.2 Ci/mMol) in PBS, 1% NP-40, 0.1 mM L-tyrosine, and 0.1 mM L-dihydroxyphenylalanine (L-DOPA). The reaction was carried out at 37°C for 1 h, and terminated by addition of 0.2 ml of a charcoal suspension (100 mg/ml in 0.1 M citric acid). After 30 min on ice, the samples were centrifuged and an aliquot was counted in a scintillation counter (LS 9000; Beckman Instruments, Inc., Fullerton, CA). All assays were performed in duplicate. Controls included $^3\text{H}_2\text{O}$ release measured in lysates from the human renal carcinoma cell line SK-RC-7 and reaction mixture in PBS, 1% NP-40 alone. Specific tyrosinase activity was calculated as follows: ($^3\text{H}_2\text{O}$ release by test cell lysate) - ($^3\text{H}_2\text{O}$ release by control reaction mixture in PBS). Protein concentrations were determined by the Bradford's dye binding method using the Protein Assay Kit (Bio-Rad Laboratories, Richmond, CA). For melanin assays, 3×10^6 cells were solubilized in 0.5 ml Protosol (New England Nuclear) and kept on ice for 2 h. An absorption baseline was established using Protosol, and absorption spectra for cell extracts were determined between 320 and 450 nm and compared against a melanin control, 100 $\mu\text{g}/\text{ml}$, in Protosol.

Results

Isolation and Sequencing of the cDNA Clone BBTY-1. cDNA clones were isolated from a λ gt10 library derived from the pigmented human melanoma cell line SK-MEL-19 (see Materials and Methods). 10^5 recombinant cDNA clones were screened and four reactive clones were plaque purified. The four cDNA inserts were subcloned into the plasmid vector pUC 18 and clones were designated pBBTY-1, -2, -3, and -4. Two clones, pBBTY-1 and pBBTY-2, each containing cDNA inserts of 2 kb, had restriction maps identical to each other and to that of Pmel 34, reported by Kwon et al. (1) (digested with Bgl II, Hpa II, Msp I, Nco I, Pvu II, and Taq I). The cDNA inserts in clones pBBTY-3 and pBBTY-4 were 1.7 and 1.8 kb, respectively. The restriction map of pBBTY-3 was different from those of pBBTY-1 and pBBTY-2 downstream of position 960 (a Pvu II restriction site). pBBTY-1 was subsequently sequenced and used for further experiments.

The nucleotide sequence of BBTY-1 (Fig. 1) contained a single open reading frame of 1,593 residues capable of encoding a 531-aa polypeptide with a derived molecular mass of 60.37 kD. A leader peptide of 19 aa was assigned to positions -19 through -1 (23). The processed core protein was predicted to have a molecular mass of 58.11 kD. Seven potential *N*-glycosylation signals (Asn-X-Ser/Thr) were predicted at positions 69, 94, 144, 213, 273, 320, and 354. Based on a hydrophobicity plot, according to the method of Kyte and Doolittle (24), a transmembrane region was predicted within a highly hydrophobic domain between aa positions 470 and 490. There was a 318 base 3' noncoding region that contained an atypical polyadenylation signal, AATTAAA (25). The nucleotide and aa sequences of BBTY-1 were nearly identical to the sequence of the Pmel 34 cDNA. (1). However, BBTY-1 contained an additional upstream 5' sequence, including a potential initiation codon not present in Pmel 34 (bases 1-7). There were also differences in the predicted aa sequence of BBTY-1 at positions 25-28, 162, 291, 356-361, 385, 478, and 503-512. The predicted molecular size of the processed protein coded by BBTY-1 was smaller than the processed

```

-19 Gly Arg Met Leu Leu Ala Val Leu Tyr Cys Leu Leu Trp Ser Phe Gln Thr Ser Ala Gly
1 GGA AGA ATG CTC CTG GCT GTT TTG TAC TGC CTG CTG TGG AGT TTC CAG ACC TCC GCT GGC
2 His Phe Pro Arg Ala Cys Val Ser Ser Lys Asn Leu Met Glu Lys Glu Cys Cys Pro Pro
61 CAT TTC CCT AGA GCC TGT GTC TCC TCT AAG AAC CTG ATG GAG AAG GAA TGC TGT CCA CCG
22 Trp Ser Gly Asp Arg Ser Pro Cys Gly Gln Leu Ser Gly Arg Gly Ser Cys Gln Asn Ile
121 TGG AGC GGG GAC AGG AGT CCC TGT GGC CAG CTT TCA GGC AGA GGT TCC TGT CAG AAT ATC
42 Leu Leu Ser Asn Ala Pro Leu Gly Pro Gln Phe Pro Phe Thr Gly Val Asp Asp Arg Glu
181 CTT CTG TCC AAT GCA CCA CTT GGG CCT CAA TTT CCC TTC ACA GGG GTG GAT GAC CCG GAG
62 Ser Trp Pro Ser Val Phe Tyr Asn Arg Thr Cys Gln Cys Ser Gly Asn Phe Met Gly Phe
241 TCG TGG CCT TCC GTC TTT TAT AAT AAG ACC TGC CAG TGC TCT GGC AAC TTC ATG GGA TTC
-----
82 Asn Cys Gly Asn Cys Lys Phe Gly Phe Trp Gly Pro Asn Cys Thr Glu Arg Arg Leu Leu
301 AAC TGT GGA AAC TGC AAG TTT GGC TTT TGG GGA CCA AAC TGC ACA GAG AGA CGA CTC TTG
-----
102 Val Arg Arg Asn Ile Phe Asp Leu Ser Ala Pro Glu Lys Asp Lys Phe Phe Ala Tyr Leu
361 GTG AGA AGA AAC ATC TTC GAT TTG AGT GCC CCA GAG AAG GAC AAA TTT TTT GCC TAC CTC
122 Thr Leu Ala Lys His Thr Ile Ser Ser Asp Tyr Val Ile Pro Ile Gly Thr Tyr Gly Gln
421 ACT TTA GCA AAG CAT ACC ATC AGC TCA GAC TAT GTC ATC CCC ATA GGG ACC TAT GGC CAA
142 Met Lys Asn Gly Ser Thr Pro Met Phe Asn Asp Ile Asn Ile Tyr Asp Leu Phe Val Trp
481 ATG AAA AAT GGA TCA ACA CCC ATG TTT AAC GAC ATC AAT ATT TAT GAC CTC TTT GTC TGG
-----
162 Ile His Tyr Tyr Val Ser Met Asp Ala Leu Leu Gly Gly Tyr Glu Ile Trp Arg Asp Ile
541 ATC CAT TAT TAT GTG TCA ATG GAT GCA CTG CTT GGG GGA TAT GAA ATC TGG AGA GAC ATT
182 Asp Phe Ala His Glu Ala Pro Ala Phe Leu Pro Trp His Arg Leu Phe Leu Leu Arg Trp
601 GAT TTT GCC CAT GAA GCA CCA GCT TTT CTG CCT TGG CAT AGA CTC TTC TTG TTG CCG TGG
202 Glu Gln Glu Ile Gln Lys Leu Thr Gly Asp Glu Asn Phe Thr Ile Pro Tyr Trp Asp Trp
661 GAA CAA GAA ATC CAG AAG CTG ACA GGA GAT GAA AAC TTC ACT ATT CCA TAT TGG GAC TGG
-----
222 Arg Asp Ala, Glu Lys Cys Asp Ile Cys Thr Asp Glu Tyr Met Gly Gly Gln His Pro Thr
721 CCG GAT GCA GAA AAG TGT GAC ATT TGC ACA GAT GAG TAC ATG GGA GGT CAG CAC CCC ACA
242 Asn Pro Asn Leu Leu Ser Pro Ala Ser Phe Phe Ser Ser Trp Gln Ile Val Cys Ser Arg
781 AAT CCT AAC TTA CTC AGC CCA GCA TCA TTC TTC TCC TCT TGG CAG ATT GTC TGT AGC CGA
262 Leu Glu Glu Tyr Asn Ser His Gln Ser Leu Cys Asn Gly Thr Pro Glu Gly Pro Leu Arg
841 TTG GAG GAG TAC AAC AGC CAT CAG TCT TTA TGC AAT GGA ACG CCC GAG GGA CCT TTA CCG
-----
282 Arg Asn Pro Gly Asn His Asp Lys Ser Arg Thr Pro Arg Leu Pro Ser Ser Ala Asp Val
901 CGT AAT CCT GGA AAC CAT GAC AAA TCC AGA ACC CCA AGG CTC CCC TCT TCA GCT GAT GTA
302 Glu Phe Cys Leu Ser Leu Thr Gln Tyr Glu Ser Gly Ser Met Asp Lys Ala Ala Asn Phe
961 GAA TTT TGC CTG AGT TTG ACC CAA TAT GAA TCT GGT TCC ATG GAT AAA GCT GCC AAT TTC
-----
322 Ser Phe Arg Asn Thr Leu Glu Gly Phe Ala Ser Pro Leu Thr Gly Ile Ala Asp Ala Ser
1021 AGC TTT AGA AAT ACA CTG GAA GGA TTT GCT AGT CCA CTT ACT GGG ATA GCG GAT GCC TCT
---
342 Gln Ser Ser Met His Asn Ala Leu His Ile Tyr Met Asn Gly Thr Met Ser Gln Val Gln
1081 CAA AGC AGC ATG CAC AAT GCC TTG CAC ATC TAT ATG AAT GGA ACA ATG TCC CAG GTA CAG
-----
362 Gly Ser Ala Asn Asp Pro Ile Phe Leu Leu His His Ala Phe Val Asp Ser Ile Phe Glu
1141 GGA TCT GCC AAC GAT CCT ATC TTC CTT CTT CAC CAT GCA TTT GTT GAC AGT ATT TTT GAG
382 Gln Trp Leu Arg Arg His Arg Pro Leu Gln Glu Val Tyr Pro Glu Ala Asn Ala Pro Ile
1201 CAG TGG CTC CGA AGG CAC CGT CCT CTT CAA GAA GTT TAT CCA GAA GCC AAT GCA CCC ATT
402 Gly His Asn Arg Glu Ser Tyr Met Val Pro Phe Ile Pro Leu Tyr Arg Asn Gly Asp Phe
1261 GGA CAT AAC CCG GAA TCC TAC ATG GTT CCT TTT ATA CCA CTG TAC AGA AAT GGT GAT TTC
422 Phe Ile Ser Ser Lys Asp Leu Gly Tyr Asp Tyr Ser Tyr Leu Gln Asp Ser Asp Pro Asp
1321 TTT ATT TCA TCC AAA GAT CTG GGC TAT GAC TAT AGC TAT CTA CAA GAT TCA GAC CCA GAC
442 Ser Phe Gln Asp Tyr Ile Lys Ser Tyr Leu Glu Gln Ala Ser Arg Ile Trp Ser Trp Leu
1381 TCT TTT CAA GAC TAC ATT AAG TCC TAT TTG GAA CAA GCG AGT CCG ATC TGG TCA TGG CTC
462 Leu Gly Ala Ala Met Val Gly Ala Val Leu Thr Ala Leu Leu Ala Gly Leu Val Ser Leu
1441 CTT GGG GCG GCG ATG GTA GGG GCC GTC CTC ACT GCC CTG CTG GCA GGG CTT GTG AGC TTG
482 Leu Cys Arg His Lys Arg Lys Gln Leu Pro Glu Glu Lys Gln Pro Leu Leu Met Glu Lys
1501 CTG TGT CGT CAC AAG AGA AAG CAG CTT CCT GAA GAA AAG CAG CCA CTC CTC ATG GAG AAA
502 Glu Asp Tyr His Ser Leu Tyr Gln Ser His Leu
1561 GAG GAT TAC CAC AGC TTG TAT CAG AGC CAT TTA TAAAGGCTTAGGCAATAGTAGGGCCAAAAAGC
1628 CTGACCTCACTCTAACTCAAAGTATGTCCAGGTTCCAGAGAATATCTGCTGGTATTTTCTGTAAGACCATTTGCA
1707 AAATTGTAACCTAATACAAAGTGTAGCCTTCTCCAACCTCAGGTAGAACAACCTGTCTTTGTCTTGTCTTCACTC
1786 AGCCCTTTTAAACATTTCCCTAAGCCCATATGTCTAAGGAAAGGATGCTATTTGGTAATGAGGAACCTGATTTTGTAT
1865 GTGAATTAAGTGCTCTTATTTTAAAAAA

```

FIGURE 1. Nucleotide and predicted amino acid sequence of BBTY-1 cDNA. The nucleotide sequence is numbered in the 5' to 3' direction. Residues of a predicted signal peptide are indicated by negative numbers, and a cleavage site by a vertical arrow. Termination site (TAA) and polyadenylation signal (1869-1875) are underlined. Potential glycosylation sites are designated by dashed lines. These sequence data have been submitted to the EMBL/GenBank Data Libraries under the accession number Y00819.

protein predicted from Pmel 34 (62.16 kD). Based on this sequence analysis, BBTY-1 was a candidate for a full-length cDNA clone encompassing a complete coding region.

Transcription of BBTY-1 in Human Melanoma Cells. BBTY-1 cDNA was used to detect mRNA transcripts in Northern blot analysis of a panel of melanoma cell lines, including those known to express tyrosinase activity as well as tyrosinase-negative melanomas. The major transcript detected was 2.4 kb, but a weaker signal was seen at 4.7 kb (Fig. 2). Three groups of melanomas were observed based on Northern blot analysis using poly (A)⁺-selected RNA (data not shown). (a) mRNA was detected in nine pigmented melanomas that express tyrosinase activity; (b) no mRNA was detected in five nonpigmented, tyrosinase-negative melanomas; and (c) mRNA was detected in three nonpigmented, tyrosinase-negative melanomas. There was little or no difference in the intensity of mRNA signal detected in group *c* vs. *a*. No transcript was detected in mRNA from the B cell lymphoma cell line Daudi or from the T cell leukemia cell line HUT-78.

Melanin Synthesis in L929 Cells Transfected with BBTY-1. BBTY-1 was transfected into L929 mouse fibroblasts using the expression vector pcEXV-3 (11). L929 cells transfected with pcTYR (sense orientation) were designated LpcTYR. Control cells transfected with pcTYW (antisense orientation) were designated LpcTYW, and, with the plasmid pUC 18, were designated LpC. LpcTYR cells contained pigment, while no pigmentation was detected in LpcTYW, LpC, or untransfected L929 cells. As shown in Fig. 3, the cell pellets of LpcTYR clones were dark brown in contrast to the nonpigmented pellets of LpcTYW and LpC cultures.

Cell pellets of LpcTYR were more deeply pigmented when cultures were harvested at confluency. LpcTYR clones have continued to produce pigment for >5 mo in continuous culture. To confirm that the pigment in LpcTYR has the characteristics of melanin, absorption spectra of cell extracts from LpcTYR and control L929 cells were compared with those of extracts of the pigmented melanoma cell line SK-MEL-19 and purified melanin. LpcTYR and SK-MEL-19 extracts and melanin had identical patterns of absorption, with broad absorption from 360 to >450 nm; this absorption pattern was not observed with L929 cell extracts (data not shown). The absorption patterns by extracts of LpcTYR and SK-MEL-19 and melanin standard were identical to the previously described absorption spectra for melanin (26).





FIGURE 2. Northern blot analysis of poly (A)⁺-selected RNA (4 μ g/lane) from two pigmented melanoma cell lines that express tyrosinase and the B cell lymphoma cell line Daudi. The blot was hybridized with the ³²P-labeled insert of pBBTY-1. Lanes 1, SK-MEL-23 melanoma; lane 2, SK-MEL-19 melanoma; lane 3, Daudi.



1 **2** **3** **4**

FIGURE 3. Cell pellets of L929 cells transfected with sense BBTY-1 (LpTYR cell line), antisense BBTY-1 (LpTYW cell line), or pUC 18 plasmid (LpC cell line). LpTYR and LpTYW cell lines were transfected with BBTY-1-inserted sense or antisense into the expression vector pcEXV3. LpTYR-1 and LpTYR-2 are subclones of LpTYR. (1) LpC cell pellet (nonpigmented); (2) LpTYW (nonpigmented); (3) LpTYR-1 (pigmented); and (4) LpTYR-2 (pigmented).

Small clusters of cell containing dark cytoplasmic inclusions were observed throughout the LpTYR culture by light microscopy (Fig. 4). These clusters of cells always comprised a minority of the culture population. Occasional black round cells were detected floating in the tissue culture medium, perhaps related to cytostatic or cytotoxic effects of melanin by-products, and the prevalence of these cells increased as the culture reached confluency. Transmission EM revealed that LpTYR cells, but not control LpC cells, had cytoplasmic membrane-bound vesicles (Fig. 5) containing electron-dense material consistent with melanin. There was no evidence of melanosomal structural elements within LpTYR cells or LpC cells.

Tyrosinase Activity in L929 Cells Expressing BBTY-1. To confirm that the BBTY-1 product was human tyrosinase, tyrosine hydroxylase activity was measured in protein extracts of subclones of LpTYR, LpTYW, and LpC. Cell extracts from two subclones of LpTYR, designated LpTYR-1 and LpTYR-2, expressed levels of tyrosinase activity that were comparable with levels in the pigmented human melanoma cell line SK-MEL-19 (Fig. 6). In contrast, extracts of LpTYW and LpC contained no detectable tyrosinase activity.

Analysis of Expression of Melanosomal Antigens in LpTYR Cells. LpTYR-2, SK-MEL-19 melanoma cells, and control L929 cells were metabolically labeled with ^{35}S -methionine and cell extracts were immunoprecipitated with rabbit antityrosinase antiserum or mAb TA99 (which detects the melanosomal antigen gp75). In addition,




FIGURE 4. LpcTYR cells in culture. A nest of cells in the middle of the field contains large, pigmented cytoplasmic granules. ($\times 320$).

mAb 2G10 (from Dr. Pier Natali, Regina Elena Instituto, Rome), which is also directed against an intracellular 75-kD antigen expressed by pigmented melanoma cells (17), was tested. Antityrosinase antiserum detected a 75-kD protein in LpcTYR-2 cells and a protein of the same size in SK-MEL-19 melanoma cells (Fig. 7). The molecular size




FIGURE 5. Transmission electron micrographs of segments of LpcTYR cells. (A) Cytoplasmic membrane-bound vesicles containing electron-dense material are indicated by arrows. One scale bar represents $1 \mu\text{m}$. ($\times 8,400$). (B) Higher magnification field of a cytoplasmic membrane-bound vesicle containing pigment. One scale bar represents $1 \mu\text{m}$. ($\times 16,800$).




FIGURE 6. Expression of tyrosinase activity in cell extracts from: SK-MEL 19 melanoma; Lpc cells (transfected with pUC 18 plasmid); LpcTYR-1 cells (transfected with a BBTY-1 sense construct); LpcTYR-2 cells (transfected with a BBTY-1 sense construct); and LpcTYW cells (transfected with a BBTY-1 anti-sense construct). Tyrosine hydroxylase activity is expressed as cpm $^3\text{H}_2\text{O}/\text{min}/\text{mg}$ protein (\square) or cpm $^3\text{H}_2\text{O}/\text{min}/5 \times 10^6$ cells (▨).




FIGURE 7. Immunoprecipitation of lysates from ^{35}S -methionine metabolically labeled SK-MEL-19 melanoma cells, LpcTYR-2 cells expressing BBTY-1, and L929 cells. Lane 1, mAb TA99; lane 2, mAb 2G10; lane 3, control rabbit sera; and lane 4, rabbit anti-tyrosinase antisera. A 75-kD band is detected in SK-MEL-19 (with TA99, 2G10, and anti-tyrosinase) and LpcTYR-2 cells (with anti-tyrosinase). Molecular weight standards: Myosin M chain (200 kD); phosphorylase (96 kD); BSA (68 kD); and OVA (43 kD).

of tyrosinase in LpcTYR-2 and SK-MEL-19 cells corresponded to the size of glycosylated tyrosinase. A very faint band at ~ 75 kD was inconsistently detected in L929 cells with antityrosinase antiserum; this likely represents a crossreaction of polyclonal sera to a nontyrosinase molecule in L929 cells, since no tyrosinase activity or tyrosinase transcript was detected in these cells and cold lysates from L929 cells did not block immunoprecipitation of tyrosinase from LpcTYR-2 (data not shown).

No specific bands were detected by either mAb TA99 or mAb 2G10 in LpcTYR-2 extracts, although both antibodies precipitated a broad 75-kD band from melanoma SK-MEL-19 lysates. These results were confirmed using immunofluorescence assays. Neither mAb TA99 nor 2G10 stained LpcTYR cells but both reacted with SK-MEL-19 cells (Fig. 8). In addition, mAb CF21, directed against a melanosomal antigen of unknown molecular size, did not react with LpcTYR but stained SK-MEL-19 (Fig. 8). We conclude that mAbs TA99, CF21, and 2G10 identify antigens distinct from tyrosinase encoded by the BBTY-1 cDNA clone.




FIGURE 8. Indirect immunofluorescence assays for antigen expression by: (A) LpTYR-2 cells expressing BBTY-1; and (B) SK-MEL-19 melanoma cells. mAb TA99 (anti-gp75) (Δ); mAb CF21 (antimelanosomal antigen) (\bullet); mAb H100-5R28 (anti-H-2^b) (\circ); and mAb AJ2 (antiintegrin; positive control) (\blacktriangle).

Discussion

Tyrosinase catalyzes the *o* hydroxylation of monophenols and oxidation of *o*-diphenols to *o*-quinones. In melanocytic cells, tyrosinase enzymatically converts tyrosine to DOPA, and DOPA to dopaquinone, leading to the spontaneous formation of the complex mixture of pigments known as melanin (27). The later steps in this pathway are not well characterized, and it has been suggested that a number of other factors, both catalytic and inhibitory, may regulate melanin synthesis and influence the species of melanin formed (28, 29). The complexity of pigment expression has been further highlighted by genetic studies in the mouse where >50 loci have been found to influence coat color (30). Thus, it is possible that a number of gene products, most not yet identified, can play a role in melanogenesis.

It is remarkable that transfected L929 fibroblasts not only stably expressed tyrosinase activity but were able to produce and package melanin. Melanin precursors are cytotoxic, and it has been presumed that melanocytic cells contain mechanisms, perhaps located within melanosomes, that protect from the effects of toxic intermediates. We suspect that melanin precursors were in fact cytotoxic in transfected L929 cells, and that cells producing substantial amounts of pigment were destined to die, based on the following observations: (a) only a subpopulation of transfected cells contained pigmented vesicles; (b) deeply pigmented, nonviable cells were observed floating in the supernatant of transfectant cultures; and (c) when transfected cells were cryopreserved and then thawed, pigmented cells were not initially detected but eventually repopulated the culture.

We have not yet analyzed in detail the synthesis or processing of human tyrosinase in transfected L929 cells. From our preliminary studies, it appears that human tyrosinase is glycosylated to a form that is identical in size to fully processed tyrosinase expressed in human melanocytic cells. It is likely that human tyrosinase was processed through the Golgi apparatus in L929 cells and transported to or remained in vesicles arising from the *trans*-Golgi. The nature and destination of these vesicles is not known. It is interesting to speculate that these vesicles might be precursors of melanosomes but that formation of melanosomes would depend on the products of other specialized genes.

The expression and regulation of tyrosinase has been the subject of extensive studies, but the formal identification of the gene that codes for tyrosinase has not been straightforward (reviewed in reference 31). Two distinct, and only distantly related, genes have been proposed as candidates for mouse tyrosinase, based on detection of mRNA of these genes in melanocytic cells and reactivity of the protein product with antibodies against tyrosinase (32, 33). Neither gene, however, was demonstrated directly to code for a product with tyrosinase activity. It is likely that antibodies used to detect the products of putative tyrosinase cDNA clones reacted with other molecules that copurified with tyrosinase. This situation was recently clarified by the identification of the mouse tyrosinase gene by Müller et al. (34) who isolated a cDNA clone, pmctyrl, that coded for transient expression of tyrosinase activity in transfection assays. No pigment synthesis was reported in transfected cells, possibly because assays were performed only shortly after transfection, because the recipient cells were different (an amelanotic melanoma and a breast carcinoma cell line), or because levels of tyrosinase activity appeared to be much lower than in mouse fibroblasts transfected with BBTY-1.

The candidate for the human tyrosinase gene, designated Pmel 34, has been reported by Kwon et al. (1). Kwon et al. (35) also recently described a mouse cDNA, MTY811C, isolated using Pmel 34. The gene product encoded by MTY811C was predicted to be 81% homologous to the protein encoded by Pmel 34. Both the human Pmel 34 and the mouse MTY811C correspond to the human counterpart of the mouse pmctyrl gene, and in fact, the pmctyrl clone was also isolated by screening a cDNA library from mouse melanoma cells with the Pmel 34 cDNA. The Pmel 34 cDNA clone was detected by screening a cDNA library with polyclonal antisera raised against hamster tyrosinase. Pmel 34 has been mapped to the *c* (albino) locus in the mouse, the presumed site of the tyrosinase structural gene or a gene that regulates tyrosinase expression. The nucleotide and predicted aa sequences of BBTY-1 and Pmel 34 are nearly identical. BBTY-1 contains an initiation codon that is not present in Pmel 34, and there are minor differences in nucleotide and predicted aa sequences. It is possible that some of these differences represent genetic polymorphism or somatic mutations (related to the source of cell types used to isolate cDNA, i.e., melanoma cells for BBTY-1 vs. melanocytes for Pmel 34). It is interesting to note that where there are distinct differences in sequences between BBTY-1 and Pmel 34, the sequence of BBTY-1 is very close or identical to the mouse pmctyrl tyrosinase sequence (e.g., aa 356–361 and 385).

Multiple transcripts of the tyrosinase gene have been found in mouse melanoma cells (36). The remaining transcripts are generated by alternative splicing leading to deletion of internal sequences, presumably by exon skipping or by selection of

internal splice sites. When these alternative transcripts have been expressed, they have not been found to encode active tyrosinase (34, 36). The BBTY-1 cDNA represents the human counterpart of the mouse *pmctyl1* transcript. Another cDNA clone that we isolated, BBTY-3, differs from BBTY-1 in its 3' restriction map, possibly corresponding to an alternative transcript of the human tyrosinase gene.

We have asked what is the relationship of tyrosinase to the melanosomal/cytoplasmic antigens recognized by mAbs 2G10, TA99, and CF21. It has been shown that mAb 2G10 immunodepletes tyrosinase activity (37) and, therefore, possibly recognizes a molecule with tyrosinase activity. However, mAb 2G10 did not react with human tyrosinase encoded by BBTY-1, suggesting that mAb 2G10 recognizes a distinct molecule from the gene product of BBTY-1. TA99 mAb recognizes an acidic 75-kD glycoprotein (38), and the antigen recognized by TA99 is a candidate for tyrosinase, based on its expression in melanosomes, its molecular size, and charge. The finding that mAbs TA99 and CF21 did not react with L929 transfectants provides evidence that they do not recognize determinants coded for by the BBTY-1 human tyrosinase molecule. Further data suggest that mAb TA99 does not recognize tyrosinase: (a) mAb TA99 does not precipitate tyrosinase activity from melanoma cell extracts (39, 40); (b) the TA99 antigen, gp75, is generally coexpressed with tyrosinase activity, but there are examples of gp75⁺ melanoma cell lines that do not express tyrosinase activity; and (c) we have been able to regulate independently the expression of tyrosinase and gp75 in melanoma cell lines (20).

Understanding the specificity of mAbs that react with melanosomal antigens will be important for sorting out the identity of these molecules. It has been proposed in a recent report by Jiménez et al. (41) that a second gene only distantly related to BBTY-1 and *Pmel 34* (33), mapping to the *b* (brown) locus in the mouse (42), codes for a gene product with tyrosinase activity (41). Thus, it is becoming increasingly evident that tyrosinase is a member of a family of related molecules that include distinct genes and alternative transcripts of these genes (32–34, 36, 41, 42).

Summary

A distinguishing characteristic of cells of the melanocyte lineage is the expression of the melanosomal enzyme tyrosinase that catalyzes the synthesis of the pigment melanin. A tyrosinase cDNA clone, designated BBTY-1, was isolated from a library constructed from the pigmented TA99⁺/CF21⁺ melanoma cell line SK-MEL-19. Expression of BBTY-1 in mouse L929 fibroblasts led to synthesis and expression of active tyrosinase, and, unexpectedly, to stable production of melanin. Melanin was synthesized and stored within membrane-bound vesicles in the cytoplasm of transfected fibroblasts. BBTY-1 detected a 2.4-kb mRNA transcript in nine of nine pigmented, tyrosinase-positive melanoma cell lines. Tyrosinase transcripts of the same size and abundance were detected in a subset (three of eight) of nonpigmented, tyrosinase-negative melanoma cell lines, suggesting that post-transcriptional events are important in regulating tyrosinase activity. Two melanocyte antigens, recognized by mAbs TA99 and CF21, that are specifically located within melanosomes and are coexpressed with tyrosinase activity, did not react with transfected mouse fibroblasts expressing human tyrosinase, supporting the conclusion that these antigenic determinants are distinct from the tyrosinase molecule coded for by BBTY-1.

We thank Jeanie Melson for help in preparation of this manuscript, Peter Doskoch for technical assistance, Drs. Carlos Cordon-Cardo and Robert Erlandson for performing the EM studies, and Drs. James P. DiSanto, Kenneth O. Lloyd, Joseph A. Trapani, and Hiroo Yuasa for helpful discussions.

Received for publication 21 December 1988 and in revised form 23 February 1989.

References

1. Kwon, B. S., A. K. Haq, S. H. Pomerantz, and R. Halaban. 1987. Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse *c*-albino locus. *Proc. Natl. Acad. Sci. USA.* 84:7473.
2. Houghton, A. N., M. Eisinger, A. P. Albino, J. G. Cairncross, and L. J. Old. 1982. Surface antigens of melanocytes and melanoma: markers of melanocyte differentiation and melanoma subsets. *J. Exp. Med.* 156:1755.
3. Kit, S., D. Dubbs, L. Piekarski, and T. Hsu. 1963. Deletion of thymidine kinase activity from L cells resistant to bromodeoxyuridine. *Exp. Cell Res.* 31:297.
4. Maniatis, T., E. F. Frish, and J. Sambrook. 1982. *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 545 pp.
5. Gubler, U., and B. J. Hoffman. 1983. A simple and very efficient method of generating cDNA libraries. *Gene (Amst.)* 25:263.
6. Watson, C. J., and J. F. Jackson. 1985. Constructing and screening cDNA libraries in λ gt 10 and λ gt 11. In *DNA Cloning: A Practical Approach.* D. M. Glover, editor. IRL Press Limited, Oxford. 79-100.
7. Huynh, T. V., R. A. Young, and R. W. Davis. 1985. An alternative procedure for the synthesis of double stranded cDNA for cloning in phage and plasmid vectors. In *DNA Cloning: A Practical Approach.* D. M. Glover, editor. IRL Press Limited, Oxford. 49-78.
8. Vieira, J., and J. Messing. 1982. The pUC plasmids, and M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. *Gene (Amst.)* 19:259.
9. Henikoff, S. 1984. Unidirectional digestion with Exonuclease III creates targeted breakpoints for DNA sequencing. *Gene (Amst.)* 28:351.
10. Sanger, F., S. Nicklen, and A. Coulson. 1977. DNA sequencing with chain termination inhibitors. *Proc. Natl. Acad. Sci. USA.* 74:5463.
11. Miller, J., and R. N. Germain. 1986. Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. *J. Exp. Med.* 164:1478.
12. Wigler, M., R. Sweet, G. K. Sim, B. Wold, A. Pellicer, E. Lacy, T. Maniatis, S. Silverstein, and R. Axel. 1979. Transformation of mammalian cells with genes from procaryotes and eucaryotes. *Cell.* 16:777.
13. Lemke, H., G. Hammerling, and U. Hammerling. 1979. Fine specificity analysis with monoclonal antibodies of antigens controlled by the MHC Qa/Tl region in mice. *Immunol. Rev.* 47:175.
14. Real, F. X., A. N. Houghton, A. P. Albino, C. Cordon-Cardo, M. Melamed, H. F. Oettgen, and L. J. Old. 1985. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. *Cancer Res.* 45:4401.
15. Cairncross, J. G., J. M. Mattes, H. R. Beresford, A. P. Albino, A. N. Houghton, K. O. Lloyd, and L. J. Old. 1982. Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. *Proc. Natl. Acad. Sci. USA.* 79:5641.
16. Thomson, T. M., F. X. Real, S. Murakami, C. Cordon-Cardo, L. J. Old, and A. N. Houghton. 1988. Differentiation antigens of melanocytes and melanoma: analysis of

- melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. *J. Invest. Dermatol.* 90:459.
17. Natali, P. G., C. Appollonj, M. Cuomo, M. R. Nicotra, and P. Giacomini. 1986. A melanocyte differentiation antigen recognized by a new murine monoclonal antibody mAb. *J. Invest. Dermatol.* 87:392.
 18. Kantor, R. R. S., J. M. Mattes, K. O. Lloyd, L. J. Old, and A. P. Albino. 1987. Biochemical analysis of two cell surface glycoprotein complexes, very common antigen 1 and very common antigen 2. *J. Biol. Chem.* 262:31.
 19. Fuller, B. B., J. B. Lunsford, and D. S. Iman. 1987. Melanocyte-stimulating hormone regulation of tyrosinase in Cloudman S-91 mouse melanoma cell cultures. *J. Biol. Chem.* 262:4024.
 20. Houghton, A. N., F. X. Real, L. J. Davis, C. Cordon-Cardo, and L. J. Old. 1987. Phenotypic heterogeneity of melanoma: relation to the differentiation program of melanoma cells. *J. Exp. Med.* 164:812.
 21. Laemmli, U. K. 1970. Cleavage of structural proteins during assembly of the head of bacteriophage T4. *Nature (Lond.)* 227:680.
 22. Pomerantz, S. H. 1969. L-Tyrosine-3, 5-³H assay for tyrosinase development in skin of newborn hamsters. *Science (Wash. DC)* 164:838.
 23. Von Heijne, G. 1983. Patterns of amino acids near signal sequencing cleavage sites. *Eur. J. Biochem.* 133:17.
 24. Kyte, J., and R. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. *J. Mol. Biol.* 157:105.
 25. Wilkins, M., and P. Stephenson. 1984. Role of the conserved AAU-AAA sequence from AAUAAA point mutants prevent mRNA 3' end formation. *Science (Wash. DC)* 226:1045.
 26. Oikawa, A., and M. Nakayasu. 1973. Quantitative measurement of melanin as tyrosine equivalents and as weight of purified melanin. *Yale J. Biol. Med.* 46:500.
 27. Mason, H. S. 1948. The chemistry of melanin. III. Mechanism of the oxidation of dihydroxyphenylalanine and tyrosinase. *J. Biol. Chem.* 172:83.
 28. Pawelek, J., and A. B. Lerner. 1978. 5-6 dihydroxyindole is a melanin precursor showing potent cytotoxicity. *Nature (Lond.)* 276:627.
 29. Pawelek, J., A. Körner, A. Bergstrom, and J. Bologna. 1980. New regulators of melanin biosynthesis and the autodestruction of melanoma cells. *Nature (Lond.)* 186:617.
 30. Silvers, W. K. 1979. *The Coat Colors of Mice: A Model for Mammalian Gene Action and Interaction.* Springer-Verlag, Berlin. 379 pp.
 31. Hearing, V. J., and M. Jimenez. 1989. Analysis of mammalian pigmentation at the molecular level. *Pigm. Cell Res.* 2:75.
 32. Yamamoto, H., S. Takeuchi, T. Kudo, K. Makino, A. Nakata, T. Shinoda, and T. Takeuchi. 1987. Cloning and sequencing of mouse tyrosinase cDNA. *Jpn. J. Genet.* 62:271.
 33. Shibahara, S., Y. Tomita, T. Sakuhara, C. Nager, B. Chaudhuri, and R. Nuller. 1986. Cloning and expression of cDNA encoding mouse tyrosinase. *Nucleic Acids Res.* 14:2413.
 34. Müller, G. S., E. Ruppert, E. Schmid, and G. Schutz. 1988. Functional analysis of alternatively spliced tyrosinase gene transcripts. *EMBO (Eur. Mol. Biol. Organ.) J.* 7:2723.
 35. Kwon, B. S., M. Wakulchik, A. K. Haq, R. Halaban, and D. Kestler. 1988. Sequence analysis of mouse tyrosinase cDNA and the effect of melanotropin on its gene expression. *Biochem. Biophys. Res. Commun.* 153:1301.
 36. Ruppert, S., G. Müller, B. Kwon, and G. Schutz. 1988. Multiple transcripts of the mouse tyrosinase gene are generated by alternative splicing. *EMBO (Eur. Mol. Biol. Organ.) J.* 7:2715.
 37. Kwon, B. S., R. Halaban, G. S. Kim, L. Usack, S. Pomerantz, and A. K. Haq. 1987. A melanocyte-specific complementary cDNA clone whose expression is inducible by melanotropin and isobutylmethyl xanthine. *Mol. Biol. Med.* 4:339.

38. Tai, T., M. Eisinger, S. Ogata, and K. O. Lloyd. 1983. Glycoproteins as differentiation markers in human malignant melanoma and melanocytes. *Cancer Res.* 43:2773.
39. Mattes, J., T. M. Thomson, L. J. Old, and K. O. Lloyd. 1983. A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. *Int. J. Cancer.* 32:717.
40. Thomson, T. M., J. Mattes, L. Roux, L. J. Old, and K. O. Lloyd. 1985. Pigmentation-associated glycoprotein of human melanomas and melanocytes: definition with a mouse monoclonal antibody. *J. Invest. Dermatol.* 85:169.
41. Jiménez, M., W. L. Maloy, and V. J. Hearing. 1989. Specific identification of an authentic clone for mammalian tyrosinase. *J. Biol. Chem.* 264:3397.
42. Jackson, I. T. 1988. A cDNA encoding tyrosinase-related protein maps to the *brown* locus in mouse. *Proc. Natl. Acad. Sci. USA.* 85:4392.